^
Association details:
| Biomarker: | PIK3CA mutation |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | everolimus (mTOR inhibitor) + SNX-631 (CDK19 inhibitor, CDK8 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PD5-10 Dual therapeutic targeting of CDK8/19 and mTOR in triple negative breast cancer
Published date:
11/22/2022
Excerpt:
We also analyzed the effect of CDK8/19 inhibition on the outcome of treatment with mTORC1 inhibitor everolimus (RAD001), an approved drug for several cancers with mutations of PTEN or PI3KCA. SNX631 exhibited a synergistic effect in combination with everolimus on suppressing TNBC cell growth in vitro.
